Abstracts tagged "corticosteroids"

Abstract Number: 0111 • ACR Convergence 2020
Assessment and Treatment of Glucocorticoid-Induced Osteoporosis in a Rheumatology Clinic
Amanda Stefl¹, Shikha Singla², Jessica Michaud¹, Kama Thomas², Lisa Rein² and Mary Ellen Csuka², ¹Froedtert Hospital, Milwaukee, WI, ²Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Glucocorticoids (GC) are used as a long-term treatment option for an estimated 1% of the US population. The American College of Rheumatology has maintained…
Abstract Number: 0113 • ACR Convergence 2020
Improving Glucocorticoid-Induced Osteoporosis Screening and Management in Patients with Rheumatic Diseases Using the 2017 ACR Guidelines
Marielys Figueroa Sierra¹, Atefeh Vafa¹, Shu Cao², Yuanyuan Lu³, Helen Bateman⁴, John Carter¹, Yih Chang Lin², Raquel Cuchacovich¹, Marcos Maldonado⁴, Joanne Valeriano-Marcet¹ and Gabriela Montes-Rivera⁴, ¹University of South Florida, Tampa, FL, ²University of South Florida, Morsani College of Medicine, Tampa, FL, ³Biostatistician at Graduate Medical Education Department, Tampa, FL, ⁴James A. Haley VA, Tampa, FL
Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is a potentially preventable complication in those who are maintained on glucocorticoid (GC) therapy. It is imperative to identify these patients…
Abstract Number: 0404 • ACR Convergence 2020
Isolated Aortitis: Single Centre Experience of Clinical Spectrum and Management
Nadia Ahmad¹, Ayna Verdiyeva², Raashid Luqmani² and Shirish Dubey², ¹Oxford University Hospitals NHS Foundation Trust, Reading, United Kingdom, ²Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
Background/Purpose: Aortitis was previously regarded as a rare form of large vessel vasculitis (LVV), but is now increasingly being recognised. It may occur in the…
Abstract Number: 0466 • ACR Convergence 2020
Dosage Modification of Immunomodulatory Medications by Rheumatology Patients in New York City During the Peak of the COVID-19 Pandemic
Marianna Frey¹, Gregory Vitone², Candace Feldman³, Lindsay Lally¹, Anne Bass⁴, Jane Salmon¹, Mary Crow¹, Michael Lockshin⁵, Vivian Bykerk¹, Lisa Mandl¹ and Medha Barbhaiya⁵, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, ³Brigham and Women's Hospital, Boston, ⁴Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY
Background/Purpose: Due to concerns about underlying immune dysregulation and immunosuppression, patients with systemic rheumatic diseases living in COVID-19 “hot spots” may have modified their immunomodulatory…
Abstract Number: 0872 • ACR Convergence 2020
Usage of Corticosteroids and Hospitalisation Duration in Adult Patients with Systemic Lupus Erythematosus (SLE) in Latvia
Ilze Vinkalna¹, Inita Bulina², Natalija Vellere², Kristine Ivanova², Pauls Rubins², Renate Diura², Santa Mikena², Julija Zepa² and Daina Andersone², ¹Pauls Stradins Clinical University Hospital, Rīga, Latvia, ²Pauls Stradins Clinical University Hospital, Riga
Background/Purpose: To determine the factors influencing hospitalisation duration, re – hospitalisation (more than 1 hospitalisation during the study period), frequency of the usage of corticosteroids…
Abstract Number: 1014 • ACR Convergence 2020
Disease Modifying Anti-rheumatic Drugs, Biologics and Corticosteroid Use in Older Patients with Rheumatoid Arthritis over 20 Years
John Hanly¹ and Lynn Lethbridge², ¹Dalhousie University, Halifax, NS, Canada, ²Dalhousie University, Halifax, Canada
Background/Purpose: The objective of the current study was to examine the change in prescribing patterns for older adults with RA over a 20 year period…
Abstract Number: 1569 • ACR Convergence 2020
Immune Related Adverse Events Related to Check Point Inhibitors Among Outpatients in an Academic Center
Bushra Akram¹, Aleena Itani¹, Mohammad Razaq², Samera Vaseer¹, Sara Vesely¹ and Pawan Acharya¹, ¹University of Oklahoma Health Sciences Center, Oklahoma City, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Immune check point inhibitors (ICIs) allow the body to recognize tumor cells as non-self, resulting in immune-cell mediated tumor cell destruction. These therapies have the…
Abstract Number: 1571 • ACR Convergence 2020
Distinct T Cell Responses in Inflammatory Arthritis Associated with Combined CTLA-4 and PD-1 Inhibitor Therapy
Sang Kim¹, Jean Tayar², Maria Suarez-Almazor³, Huifang Lu⁴, Yang-Zhi Zhao⁵, Margarita Divenko⁵, William Padron⁵, Emma Rodriguez⁵, Sattva Neelapu⁵, Jennifer Wang⁵, Amish Shah⁵, Nizar Tannir⁵, Don Gibbons⁵, Guillermo Garcia-Manero⁵, Hussein Tawbi⁵, Patrick Hwu⁵, Andrew Futreal⁵, Adi Diab⁵ and Roza Nurieva⁵, ¹The Univesrity of Texas MD Andesron Cancer Center, Pearland, TX, ²The University of Texas, MD Anderson Cancer Center, Houston, TX, ³University of Texas MD Anderson Cancer Center, Houston, TX, ⁴MD Anderson, Houston, TX, ⁵MD Anderson, Houston
Background/Purpose: Despite of unprecedented clinical success in cancer therapeutics, immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs), including arthritis (arthritis-irAE). Arthritis-irAE can…
Abstract Number: 1625 • ACR Convergence 2020
Pneumocystis Jiroveci Pneumonia in Immunocompromised Patients with Rheumatologic Disease in a Single, Tertiary Medical Center
Zahra Rehman¹, Megan Krause¹, Jessica Newman² and Pooja Bhadbhade¹, ¹The University of Kansas Medical Center, Kansas City, KS, ²The University of Kansas Medical Center, Kansas City
Background/Purpose: Pneumocystis jiroveci pneumonia (PJP) is rare, but can be fatal among immunocompromised. There is no consensus on indications for PJP prophylaxis in rheumatologic patients.…
Abstract Number: 1650 • ACR Convergence 2020
A Double-Blind Randomized Trial to Evaluate the Efficacy of Corticosteroid Injections for Osteoarthritis of the Knee Using Mobile Devices
Joshua Baker¹, Mitesh Patel¹, Tuhina Neogi², Keith Robinson³, Alexis Ogdie¹ and Carla Scanzello¹, ¹University of Pennsylvania, Philadelphia, PA, ²Boston University School of Medicine, Boston, MA, ³Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: The value of intra-articular (IA) corticosteroid injections for osteoarthritis of the knee (KOA) has recently been called into question. Variability in clinical trial design…
Abstract Number: 1651 • ACR Convergence 2020
Efficacy and Safety of Multiple Intra-articular Corticosteroid Injections for Osteoarthritis – a Systematic Review and Meta-analysis of Randomised Controlled Trials and Observational Studies
Shazeen Ayub¹, Jaspreet Kaur¹, Michelle Hui², Michelle Hall¹, Michael Doherty³ and Weiya Zhang¹, ¹Academic Rheumatology, School of Medicine, University of Nottingham, UK, Nottingham, United Kingdom, ²Royal Derby Hospital, Derby, UK, Derby, United Kingdom, ³Academic Rheumatology, School of Medicine, University of Nottingham, UK, Nottingham, England, United Kingdom
Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis worldwide and is becoming more prevalent with the increasing age of the population. As Intra-articular…
Abstract Number: 1652 • ACR Convergence 2020
Progression of Knee OA with Use of Intra-articular Corticosteroids (CS) vs Hyaluronic Acid (HA)
Justin Bucci¹, Xiaoyang Chen¹, James Torner², Michael Nevitt³, Cora Lewis⁴ and David Felson⁵, ¹Boston University, Boston, MA, ²University of Iowa, Iowa City, IA, ³University of California, San Francisco, Orinda, CA, ⁴University of Alabama Birmingham, Birmingham, AL, ⁵Boston University School of Medicine, Boston, MA
Background/Purpose: Recent studies have questioned whether CS injections (CSI), a popular treatment recommended by guidelines, hasten progression of knee OA. A recent cohort study suggested…
Abstract Number: 1679 • ACR Convergence 2020
Developing a Standardized Corticosteroid Dosing Regimen in Pediatric Proliferative Lupus Nephritis
Nathalie Chalhoub¹, Kelly Rouster-Stevens², Marisa Klein-Gitelman³, Karen Onel⁴, Beatrice Goilav⁵, Sonia Savani⁶, Natasha Ruth⁶, Tingting Qiu⁷, Najla Aljaberi⁸, Jianghong Deng⁹, Angela Merritt⁸, Benjamin Laskin¹⁰, Anna Carmela Sagcal-Gironella¹¹, Stacy Ardoin¹², Deborah Levy¹³, Scott Wenderfer¹⁴, Bin Huang⁷, Hermine I Brunner¹⁵ and LaUNCH Project Investigators¹⁶, ¹The University of Cincinnati College of Medicine, Cincinnati, OH, ²Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ³Division of Rheumatology, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁴Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁵The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, ⁶Medical University of South Carolina, Charleston, SC, ⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Beijing Children’s Hospital, Beijing, China (People's Republic), ¹⁰Children's Hospital of Philadelphia, Philadelphia, ¹¹Hackensack Meridian School of Medicine at Seton Hall University, Hackensack, NJ, ¹²Nationwide Children's Hospital, Columbus, OH, ¹³Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁴Renal Section, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, ¹⁵PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁶LUpus Nephritis and Cellcept precision dosing in cHildren (LaUNCH), Cincinnati, OH
Background/Purpose: Corticosteroids (CS) remain the mainstay of therapy for childhood-onset systemic lupus erythematosus (cSLE). However, widely accepted strategies for oral (PO) or intravenous (IV) CS…
Abstract Number: 1687 • ACR Convergence 2020
Kawasaki Disease Shock Syndrome in the Intensive Care Unit: A Single Center Cohort
Monica Bray¹, Jennifer Rammel², Andrea Ramirez¹, Kristen Sexson¹, Fong Lam¹, Eyal Muscal³ and Marietta DeGuzman³, ¹Baylor College of Medicine, Houston, TX, ²University of Florida Health Jacksonville, Jacksonville, FL, ³Baylor College of Medicine, Houston
Background/Purpose: Kawasaki disease (KD), a well described vasculitis of childhood, is the leading cause of acquired heart disease in developed countries. Kawasaki disease shock syndrome…
Abstract Number: 1948 • ACR Convergence 2020
Identification of Small Molecules with Efficacy as Steroid Sparing Suppression of Chemokine and Cytokine Production by Rheumatoid Arthritis Fibroblast-like Synoviocytes
Tadashi Hosoya¹, Nikunj Shukla², Yuya Fujita³, Shiyin Yao⁴, Fitzgerald Lao⁴, Hiroyuki Baba¹, Shinsuke Yasuda⁵, Howard Cottam⁴, Dennis Carson⁴, Tomoko Hayashi⁴ and Mary Corr⁶, ¹Department of Rheumatology, Tokyo Medical and Dental University (TMDU), Tokyo, Tokyo, Japan, ²Moores Cancer Center, University of California San Diego, San Diego, CA, ³Department of Medicine, University of California San Diego, San Diego, CA, ⁴Moores Cancer Center, University of California San Diego, San Diego, ⁵Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Tokyo, Japan, ⁶Department of Medicine, University of California San Diego, San Diego
Background/Purpose: Target-based drug discovery has expanded our therapeutic armamentarium in the treatment of inflammatory and autoimmune diseases. Despite these advances, glucocorticoids (GC) remain reliable agents…

1
2
3
…
7
Next Page »